Immuno Cure BioTech ("Immuno Cure"), a clinical-stage biotechnology group based in Hong Kong, China Science Park, is pleased to announce its upcoming collaboration with PharmaJet® to evaluate the safety and immunogenicity of HIV therapeutic DNA vaccine, ICVAX, delivered via PharmaJet's innovative Tropis® needle-free injection system in a clinical study. On June 16, 2025, Immuno Cure and PharmaJet held a material transfer agreement ("MTA") signing ceremony at the BIO 2025 International Convention in Boston, USA to commemorate such collaboration.

Figure 1.From left to right: Mr. Derek CHIM, Head of Startup Ecosystem and Development of Hong Kong, China Science and Technology Parks Corporation; Ms. Priscilla CHIU, Associate Director of the New Ventures Development of Hong Kong, China Science and Technology Parks Corporation; Ms. Weng-Li YOON, Associate Director of Life and Health Technology (Therapeutics) of Hong Kong, China Science and Technology Parks Corporation; Dr. Xia JIN, CEO and Co-Founder of Immuno Cure; Mr. Dan MALLON, Senior Vice President of Corporate Development of PharmaJet; Professor Zhiwei CHEN, Director of AIDS Institute and Chair Professor of the Department of Microbiology of the University of Hong Kong, China, and Principal Scientific Advisor of Immuno Cure; Ms. Hong GE, General Manager of Beijing Immuno Cure & Assistant to Group CEO; Dr. Steve CHONG, Senior Manager of Life and Health Technology (Therapeutics), of Hong Kong, China Science and Technology Parks Corporation. It captured the memorable moment after signing the MTA " HIV Therapeutic DNA Vaccine (ICVAX) Clinical Study"
HIV/AIDS remains a critical global health challenge today, despite advances in treatment and prevention. As of 2023, over 39 million people were living with HIV, and more than 40 million deaths have occurred since the start of the epidemic in 1981. Current antiretroviral therapy (&q...










(All Rights Reserved)